Vaccines are expensive and the funding is complex. From Big Pharmaceuticals to public sector, to universities, to NGOs, the UN, non-profit, not-for-profits and huge donations from private foundations, for the drug companies the trail from discovery to delivery requires deep pockets, a clear understanding of the market and ruthless commercial instincts. This programme unpicks the way we pay for vaccines and looks at who benefits. Is this a business that just serves rich shareholders – or does it deliver vaccines to the poor who need them most? And what are the recipient countries themselves doing to pay the costs? Indeed, holding developing countries to account for where the money goes is a key part of building a better future between developed and developing countries.